Fierce Pharma April 17, 2024
GlobalData has put out a forecast that shows how GLP-1 drugs could rapidly redefine what big looks like in drug sales. The analysts expect Mounjaro to bring in as much in 2029 as Eli Lilly’s entire portfolio did in 2023—and are tipping its Alzheimer’s disease prospect donanemab to add a further $5 billion.
Diabetes drug Mounjaro generated (PDF) $5.2 billion in 2023, more than 40% of which landed in Lilly’s bank account across the final three months of the year. Zepbound, the same molecule rebadged for the weight-loss market, pulled in more than $175 million in its first quarter on the market. The products underpin Lilly’s belief that its total revenue will top $40 billion this year, up from...
Today's Sponsors
Today's Sponsor